Verismo and Miltenyi Biotec's Collaboration to Enhance CAR T Cell Therapies

Verismo Therapeutics and Miltenyi Biotec Join Forces

Verismo Therapeutics, a frontrunner in the development of CAR T therapies, has announced a significant partnership with Miltenyi Biotec. This collaboration focuses on supporting the advancement of Verismo's clinical programs, particularly by supplying essential lentiviral vectors. This strategic move is poised to enhance the production of SynKIR™-110, Verismo's lead product currently undergoing Phase 1 clinical trials.

Milestone Achievement in Clinical Trials

On September 25, 2025, Verismo proudly revealed that they have successfully manufactured their first clinical cell product leveraging a lentiviral vector supplied by Miltenyi Bioindustry—a specialized division of Miltenyi Biotec dedicated to providing contract development and manufacturing organization (CDMO) services. This accomplishment is a critical milestone for Verismo as it prepares for the STAR-101 clinical trial aimed at evaluating the efficacy of SynKIR™-110, a therapy targeting the mesothelin protein, which is commonly overexpressed in certain solid tumors.

Ensuring Manufacturing Continuity

The collaboration with Miltenyi Bioindustry secures a reliable supply chain and lays the groundwork for future phases of clinical development, including the essential transition to Phase 2 trials and potential commercial applications of SynKIR™-110. Dr. Bryan Kim, CEO of Verismo Therapeutics, emphasized the importance of this partnership in scaling their efforts, thereby ensuring manufacturing continuity and readiness for advanced clinical trials.

"Our collaboration with Miltenyi Bioindustry is crucial as we scale our programs," stated Dr. Kim. He further noted that this partnership is reflective of Verismo's dedication to achieving continuous manufacturing processes crucial for clinical success.

Innovation in Gene Therapy

Miltenyi Biotec is recognized as a leader in the field of cell and gene therapies, specializing in transforming scientific advancements into practical treatments. With over 35 years of experience, Miltenyi Biotec aims to enable healthcare solutions for complex diseases, including various cancers and genetic disorders. Stefan Miltenyi, the founder and CEO of Miltenyi Biotec, expressed pride in supporting Verismo's innovative CAR T therapies, reinforcing the commitment of both organizations to improve patient outcomes through advanced therapeutic strategies.

The Unique KIR-CAR Platform

Verismo Therapeutics is the sole developer of the KIR-CAR platform, which is designed to elevate the efficacy of CAR T treatments against solid tumors. This technology employs modified receptors derived from NK cells and utilizes a dual signaling mechanism that fosters prolonged cell functionality while countering immune exhaustion. By addressing critical medical needs associated with difficult-to-treat solid tumors, Verismo's approach represents a breakthrough in CAR T therapy development.

The KIR-CAR platform's efficacy has been evidenced in preclinical trials where it showed notable success in overcoming challenges presented by hostile tumor microenvironments.

Looking Ahead

The partnership with Miltenyi Biotec not only solidifies Verismo's manufacturing capabilities but also enhances its readiness for future clinical trials and market applications. The advancements promised by the KIR-CAR platform could significantly change the landscape of CAR T therapies and provide new hope for patients battling advanced solid tumors and B-cell related disorders. As this collaboration continues to unfold, the medical community eagerly anticipates the results and potential impact of Verismo's innovative approaches in cell therapy.

For more information about Verismo Therapeutics and their pioneering research, visit their website.

Conclusion

As we witness the evolution of CAR T therapies, partnerships like the one between Verismo and Miltenyi Biotec highlight the importance of collaboration in the biotechnology sector. Together they aim to drive forth groundbreaking advancements in treating some of the most challenging medical conditions today, ensuring that innovative therapies reach patients who need them most.